You have read all your free articles, to continue reading subscribe to read the rest of this content.
Ilya Pharma is planning to submit an Investigational New Drug Application (IND) for a Phase 1/2a safety and dose finding clinical study of ILP100-Oral, the company’s investigational immunotherapy being developed for patients with immune mediated enterocolitis resulting from cancer treatment with cAlready a subscriber Login You have read all your…
Follicum has announced that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from animals. The studies were performed through two different collaborations, one with Lund University and oAlready a subscriber Login You have…
Moberg Pharma have announced that all patients in the European MOB-015 Phase 3 study have completed their last study visit. The data collection in the study were completed without any negative impact from COVID-19. The timeline remains unchanged with topline results expected by the end of the secAlready a subscriber…
Medivir has announced that the phase II study of MIV-711 in patients with osteoarthritis has been published in the journal Annals of Internal Medicine. The title of the article is "Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis", author; P.G Conaghan et al. In the saAlready a subscriber…
